Sarepta initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Sarepta with an Outperform rating and a price targets of $175. The analyst cites the company’s opportunity in Duchenne muscular dystrophy and dominant position in its domain.
https://thefly.com/landingPageNews.php?id=2891645
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.